Zelig Eshhar - Publications

Affiliations: 
Weizmann Institute of Science, Rehovot, Israel 
Area:
Oncology, Cell Biology, Genetics

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Zupančič E, Curato C, Kim JS, Yeini E, Porat Z, Viana AS, Globerson-Levin A, Waks T, Eshhar Z, Moreira JN, Satchi-Fainaro R, Eisenbach L, Jung S, Florindo HF. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29306001 DOI: 10.1016/j.nano.2017.12.011  0.44
2014 Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1018-28. PMID 24686242 DOI: 10.1038/mt.2014.41  0.44
2014 Eshhar Z, Waks T, Gross G. The emergence of T-Bodies/CAR T cells Cancer Journal (United States). 20: 123-126. PMID 24667957 DOI: 10.1097/PPO.0000000000000027  0.44
2014 Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1029-38. PMID 24572294 DOI: 10.1038/mt.2014.28  0.44
2012 Chmielewski M, Maliar A, Eshhar Z, Abken H. CAR's made it to the pancreas. Oncoimmunology. 1: 1387-1389. PMID 23243602 DOI: 10.4161/onci.22195  0.36
2012 Fishler R, Artzy-Schnirman A, Peer E, Wolchinsky R, Brener R, Waks T, Eshhar Z, Reiter Y, Sivan U. Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions. Nano Letters. 12: 4992-6. PMID 22900991 DOI: 10.1021/nl302619p  0.44
2012 Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology. 143: 1375-84.e1-5. PMID 22819865 DOI: 10.1053/j.gastro.2012.07.017  0.44
2011 Artzy-Schnirman A, Blat D, Talmon Y, Fishler R, Gertman D, Oren R, Wolchinsky R, Waks T, Benhar I, Eshhar Z, Sivan U, Reiter Y. Electrically controlled molecular recognition harnessed to activate a cellular response. Nano Letters. 11: 4997-5001. PMID 21985491 DOI: 10.1021/nl202971r  0.44
2011 Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood. 118: 975-83. PMID 21653325 DOI: 10.1182/blood-2011-02-334284  0.44
2010 Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium. Development of adoptive cell therapy for cancer: a clinical perspective. Human Gene Therapy. 21: 665-72. PMID 20408760 DOI: 10.1089/hum.2010.086  0.36
2009 Kela I, Harmelin A, Waks T, Orr-Urtreger A, Domany E, Eshhar Z. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. The Prostate. 69: 1034-44. PMID 19343735 DOI: 10.1002/pros.20950  0.44
2009 Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology. 136: 1721-31. PMID 19208357 DOI: 10.1053/j.gastro.2009.01.049  0.44
2008 Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology. 134: 2014-24. PMID 18424268 DOI: 10.1053/j.gastro.2008.02.060  0.44
2008 Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR, Eshhar Z. Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. The Prostate. 68: 530-9. PMID 18247403 DOI: 10.1002/pros.20702  0.44
2005 Eshhar Z, Waks T, Pinthus J. Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells. Discovery Medicine. 5: 259-64. PMID 20704885  0.44
2005 Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 105: 3087-93. PMID 15626734 DOI: 10.1182/blood-2004-09-3737  0.44
2004 Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. The Journal of Clinical Investigation. 114: 1774-81. PMID 15599402 DOI: 10.1172/JCI22284  0.44
2003 Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Research. 63: 2470-6. PMID 12750268  0.44
2002 David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J, Romano J, Avidor Y, Waks T, Eshhar Z, Langer SZ, Lifschitz-Mercer B, Matzkin H, Rotman G, Toporik A, et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. The Journal of Biological Chemistry. 277: 18084-90. PMID 11834722 DOI: 10.1074/jbc.M102285200  0.44
Show low-probability matches.